Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids

Shih, Vanessa; Banks, Erika; Bonine, Nicole; Harrington, Amanda; Stafkey-Mailey, Dana; Yue, Binglin; Ye, Jiatao Michael; Fuldeore, Rupali; Gillard, Patrick

doi:10.1080/03007995.2019.1642186

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to estimates, costs related to uterine fibroid are up to 34.4 billion dollars annually in the United States, 348 million in Germany, 120 million in France, and 86 million in England, surpassing the other two common cancers in women, breast cancer and ovarian cancer [ 10 , 11 ]. In addition to the direct health care expenses, indirect costs due to lost income from time off work and disability due to uterine fibroid are estimated to be 1.6 to 17.2 billion dollars annually [ 12 , 13 ]. Uterine fibroids are also related to infertility and other pregnancy complications, which can last for at least ten years of treatment and account for 4–23% of the annual costs [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

“…In addition to the direct health care expenses, indirect costs due to lost income from time off work and disability due to uterine fibroid are estimated to be 1.6 to 17.2 billion dollars annually [ 12 , 13 ]. Uterine fibroids are also related to infertility and other pregnancy complications, which can last for at least ten years of treatment and account for 4–23% of the annual costs [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990–2019: an age-period-cohort analysis for the global burden of disease 2019 study

Lou

Huang

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

Background Uterine fibroids are the most common benign neoplasm of the uterus and a major source of morbidity for women. We report an overview of trends in uterine fibroids of incidence rate, prevalence rate, years lived with disability (YLDs) rate in 204 countries and territories over the past 30 years and associations with age, period, and birth cohort. Methods The incident case, incidence rate, age-standardized rate (ASR) for incidence, prevalent case, prevalence rate, ASR for prevalence, number of YLDs, YLD rate, and ASR for YLDs were derived from the Global Burden of Disease 2019 (GBD 2019) study. We utilized an age-period-cohort (APC) model to estimate overall annual percentage changes in the rate of incidence, prevalence, and YLDs (net drifts), annual percentage changes from 10 to 14 years to 65–69 years (local drifts), period and cohort relative risks (period/cohort effects) between 1990 and 2019. Results Globally, the incident cases, prevalent cases, and the number of YLDs of uterine fibroids increased from 1990 to 2019 with the growth of 67.07%, 78.82% and 77.34%, respectively. High Socio-demographic Index (SDI) and high-middle SDI quintiles with decreasing trends (net drift < 0.0%), and increasing trends (net drift > 0.0%) were observed in middle SDI, low-middle SDI, and low SDI quintiles in annual percentage change of incidence rate, prevalence rate and YLDs rate over the past 30 years. There were 186 countries and territories that showed an increasing trend in incidence rate, 183 showed an increasing trend in prevalence rate and 174 showed an increasing trend in YLDs rate. Moreover, the effects of age on uterine fibroids increased with age and peaked at 35–44 years and then declined with advancing age. Both the period and cohort effects on uterine fibroids showed increasing trend in middle SDI, low-middle SDI and low SDI quintiles in recent 15 years and birth cohort later than 1965. Conclusions The global burden of uterine fibroids is becoming more serious in middle SDI, low-middle SDI and low SDI quintiles. Raising awareness of uterine fibroids, increasing medical investment and improving levels of medical care are necessary to reduce future burden.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990–2019: an age-period-cohort analysis for the global burden of disease 2019 study

Lou

Huang

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…In addition to the direct health care expenses, indirect costs due to lost income from time off work and disability due to uterine broid are estimated to be 1.6 to 17.2 billion dollars annually [12,13]. Uterine broids are also related to infertility and other pregnancy complications, which can last for at least ten years of treatment and account for 4-23% of the annual costs [13,14].…”

Section: Introductionmentioning

confidence: 99%

“…According to estimates, costs related to uterine broid are up to 34.4 billion dollars annually in the United States, 348 million in Germany, 120 million in France, and 86 million in England, surpassing the other two common cancers in women, breast cancer and ovarian cancer [10,11]. In addition to the direct health care expenses, indirect costs due to lost income from time off work and disability due to uterine broid are estimated to be 1.6 to 17.2 billion dollars annually [12,13]. Uterine broids are also related to infertility and other pregnancy complications, which can last for at least ten years of treatment and account for 4-23% of the annual costs [13,14].…”

Section: Introductionmentioning

confidence: 99%

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990-2019: An age- period-cohort analysis for the Global Burden of Disease 2019 study

Lou

Huang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Uterine fibroids are the most common benign neoplasm of the uterus and a major source of morbidity for women. We report an overview of trends in uterine fibroids of incidence, prevalence, years lived with disability (YLDs) in 204 countries and territories over the past 30 years and associations with age, period, and birth cohort. Methods: The incidence, prevalence, and YLDs were derived from the Global Burden of Disease 2019 (GBD 2019) study. We utilized an age-period-cohort (APC) model to estimate annual percentage changes in age-standardized rate (ASR) for incidence, ASR for prevalence, ASR for YLDs (net drifts), annual percentage changes from 10 - 14 years to 65 - 69 years (local drifts), period and cohort relative risks (period/cohort effects) between 1990 to 2019. Results: Globally, the incident cases, prevalent cases, and the number of YLDs of uterine fibroids increased from 1990 to 2019 with the growth of 67.07%, 78.82% and 77.34%, respectively. High Socio-demographic Index (SDI) and high-middle SDI quintiles with decreasing trends (net drift < 0.0%), and increasing trends (net drift > 0.0%) were observed in middle SDI, low-middle SDI, and low SDI quintiles in annual percentage change of ASR for incidence, ASR for prevalence and ASR for YLDs over the past 30 years. There were 186 countries and territories that showed an increasing trend in ASR for incidence, 183 showed an increasing trend in ASR for prevalence and 174 showed an increasing trend in ASR for YLDs. Moreover, the effects of age on uterine fibroids increased with age and peaked at 35 - 44 years and then declined with advancing age. Both the period and cohort effects on uterine fibroids showed increasing trend in middle SDI, low-middle SDI and low SDI quintiles in recent 15 years and birth cohort later than 1965. Conclusions: The global burden of uterine fibroids is becoming more serious in middle SDI, low-middle SDI and low SDI quintiles. Raising awareness of uterine fibroids, increasing medical investment and improving levels of medical care are necessary to reduce future burden.

show abstract

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists

Nagai

Asano

Sekiguchi

et al. 2023

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids

Cited by 6 publications

References 16 publications

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990–2019: an age-period-cohort analysis for the global burden of disease 2019 study

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990–2019: an age-period-cohort analysis for the global burden of disease 2019 study

Global, regional, and national time trends in incidence, prevalence, years lived with disability for uterine fibroids, 1990-2019: An age- period-cohort analysis for the Global Burden of Disease 2019 study

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists

Contact Info

Product

Resources

About